Reportedly the contract valued at circa GBP1.5m. Work on the project is expected to begin shortly and GMP manufacturing is expected to complete in early 2012.
Gordon Sherriff, chief operating officer at Angel Biotechnology, said: “We have worked with Materia Medica and the MHRA over a long period of time to address the complex regulatory path for this contract and we are delighted to have found innovative solutions that allow the project to progress.
“We are very pleased to be able to continue our commitment to working with Materia Medica and supporting regulatory compliant manufacture of its pipeline of products. Supporting clients with advanced biologics through the often complex regulatory hurdles is becoming a significant part of Angel’s service offering.”
Sergey Tarasov, senior research associate of R&D department at Materia Medica, said: “We are very pleased to sign this contract with Angel. This product is key to our product portfolio and Angel’s steadfastness to identify a regulatory compliant manufacturing route demonstrates the strong relationship our companies have built over the last 2.5 years. We look forward to working with Angel on future projects”